The systemic administration of Oncolytic Biotech's reovirus-basedReolysin is an effective monotherapy for the treatment of cancer in animal models that have high immune responses to the virus, according to research led by Patrick Lee at the University of Calgary, Canada.
Previous research has demonstrated that the immune status does not affect tumor regression in animals that have had Reolysin administered directly into tumors and also that, in an immune-competent mouse model of the disease, intravenous administration of the drug led to a significant reduction in tumor volume and that co-therapy with cyclosporine or cisplatin further reduced tumor size (Marketletter March 12).
Recent results show that animals with solid tumors that have not been pre-immunized against reovirus showed reduced tumor size when treated with systemic administration of Reolysin, and animals that had been pre-hyperimmunized (to a significantly higher level than that seen with normal infection or treatment with reovirus) showed no significant tumor regression with Reolysin alone. However, when these animals were pre-hyperimmunized with the reovirus and then pulse co-treated with Reolysin and either cyclosporine or cyclophosphamide, the same level of tumor reduction was observed as in unimmunized animals treated with Reolysin as a sole therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze